Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapeutic Approaches to HAART-induced Lipodystrophy.

Trial Profile

Therapeutic Approaches to HAART-induced Lipodystrophy.

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Metreleptin (Primary)
  • Indications Lipodystrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 22 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2013 Planned end date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top